

MDx-Chex® for Blood Culture GP (RUO)



INSTRUCTIONS FOR USE

This product has not been cleared by the U.S. Food and Drug Administration for In Vitro Diagnostic Use. The product is for Research Use Only. Not for use in diagnostic procedures. Patents Pending.

INTENDED USE

MDx-Chex® for Blood Culture GP (RUO) is an external quality control intended to be used with qualitative sample-to-answer molecular panels that detect nucleic acids from sepsis-causing gram-positive bacteria and associated antimicrobial resistance genes listed in Table 1. The MDx-Chex for Blood Culture GP (RUO) Positive and Negative Controls are composed of a buffered solution with stabilized erythrocytes and leukocytes in a matrix of blood culture media components. Positive Control: gram-positive bacteria: *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus lugdunensis*, *Streptococcus agalactiae*, *Streptococcus anginosus* group, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Enterococcus faecalis*, *Enterococcus faecium*; genus: *Bacillus* spp., *Listeria* spp., *Staphylococcus* spp., *Streptococcus* spp.; antimicrobial resistance genes: *mecA/mecC*, *vanA*, and *vanB*. Negative Control: buffered solution only. This product is not intended to replace manufacturer controls provided.

SUMMARY AND PRINCIPLES

Sepsis (defined as system inflammatory response syndrome in response to infection) is the 11th leading cause of death in the United States¹. Life-threatening bacterial and fungal sepsis currently strikes approximately 240 out of 100,000 people per year in the U.S. (750,000 total cases), with severe sepsis (associated with acute organ dysfunction) in 95 out of 100,000 people². Timely diagnosis and administration of effective treatment can significantly reduce mortality, duration of hospital stays, and costs due to sepsis.

MDx-Chex for Blood Culture GP (RUO) is an external quality control containing stabilized blood and blood culture media components, and inactivated microorganisms (9 organisms and 4 species that can cause bloodstream infection, as well as 3 genes known to confer antimicrobial resistance) resulting in a full-process, cellular-based control that simulates positive and negative blood culture samples. Use of full-process cellular controls are necessary to evaluate the entire analytical process for sample-to-results tests, including sample lysis, nucleic acid isolation and purification, hybridization, detection, and analysis, as well as impact of inhibitors and pre-analytical variables. Routine use of full-process quality controls can help identify variations in the test system that can lead to incorrect results.

REAGENTS

MDx-Chex for Blood Culture GP (RUO) contains stabilized human leukocytes and erythrocytes, and the following inactivated bacteria and bacteria components (see Table 1) in simulated blood culture media. Each control kit is supplied with 5 purple-capped 0.5mL microtubes, each containing 300µL of the Positive Control formulation, and 5 white-capped 0.5mL microtubes, each containing 300µL of the Negative Control formulation.

PRECAUTIONS

- MDx-Chex for Blood Culture GP (RUO) is for Research Use Only. Not for use in diagnostic procedures.
- CAUTION:** All blood products should be treated as potentially infectious. All human source material used to manufacture this product was previously established to be negative for the target analytes by a third party; non-reactive for antigens to Hepatitis B (HBsAg), negative by tests for antibodies to HIV (HIV-1/HIV-2) and Hepatitis C (HCV), non-reactive for HIV-1 RNA, and HCV RNA by licensed NAT, and non-reactive to Serological Test for Syphilis (STS), West Nile Virus and Chagas disease. Because no known test method can assure complete absence of human pathogens, this product should be handled with appropriate precautions.
- CAUTION:** All bacterial products should be treated as potentially infectious. Source material from which this product was derived was inactivated and tested in accordance with CDC/USDA "Guidance on the Inactivation or Removal of Select Agents and Toxins for Future Use." These procedures cannot offer assurance that products containing bacteria are non-infectious.
- These RUO lots should not be disposed of in general waste but should be disposed of with infectious medical waste. Disposal by incineration is recommended.
- These RUO lots are intended for use as supplied. Adulteration by dilution or addition of any materials to the tubes invalidates the use of the product.

STORAGE

MDx-Chex for Blood Culture GP (RUO) is stored at 2 °C to 25 °C.

INDICATION OF PRODUCT DETERIORATION

Discoloration of the product may be caused by overheating or freezing during shipping or storage. Dark colored (gross hemolysis) supernatant may be indicative of product deterioration. However, light colored (moderate hemolysis) or cloudy supernatant is normal and should not be confused with deterioration of the product.

INSTRUCTIONS FOR USE

Adding Control Sample

- Control samples should be processed in control mode when required per manufacturer's instructions or when given as an option for sample-to-results tests.
- If refrigerated, remove tubes of control from the refrigerator and allow to sit at room temperature to acclimate for 15 minutes before use. Vortex the Positive and Negative Control tubes at a high speed for 30 seconds. **Note: Always use aseptic technique when handling control tubes to prevent cross-contamination or environmental contamination.**
 - Verify the control tube has been adequately mixed by inverting the tube and examining the bottom for the absence of cellular material.
 - Flash spin the control to remove material from cap.
 - Open the tube and mix the control via pipet by repeatedly pipetting up and down 5-10 times.
- Remove 300µL of sample and process according to the manufacturer's instructions for sample-to-results tests.
 - Each control tube has sufficient volume for one test and can be discarded after use.
- Repeat Steps 1-3 with Negative Control.

LIMITATIONS

MDx-Chex for Blood Culture GP (RUO) should be used in accordance with local, state, federal regulations, and accreditation requirements.

EXPECTED RESULTS

All organisms and resistance genes stated in the control should be "Detected," "Not Detected," or "Not Reviewed," as indicated (see Table 1).

Table 1: MDx-Chex for Blood Culture GP (RUO) Positive Control and Negative Control Results Summary

Gram-Positive Bacteria		
Pathogen/Species	Positive Control	Negative Control
<i>Bacillus</i> spp.	Detected	Not Detected
<i>Listeria</i> spp.	Detected	Not Detected
<i>Staphylococcus</i> spp.	Detected	Not Detected
<i>Staphylococcus aureus</i>	Detected	Not Detected
<i>Staphylococcus epidermidis</i>	Detected	Not Detected
<i>Staphylococcus lugdunensis</i>	Detected	Not Detected
<i>Streptococcus</i> spp.	Detected	Not Detected
<i>Streptococcus agalactiae</i>	Detected	Not Detected
<i>Streptococcus anginosus</i> group	Detected	Not Detected
<i>Streptococcus pneumoniae</i>	Detected	Not Detected
<i>Streptococcus pyogenes</i>	Detected	Not Detected
<i>Enterococcus faecalis</i>	Detected	Not Detected
<i>Enterococcus faecium</i>	Detected	Not Detected
Antimicrobial Resistance Genes		
Gene	Positive Control	Negative Control
<i>mecA/mecC</i>	Detected	Not Reviewed
<i>vanA</i>	Detected	Not Reviewed
<i>vanB</i>	Detected	Not Reviewed

REFERENCES

- National Vital Statistics Reports, Deaths: Preliminary Data for 2010. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_04.pdf.
- Angus, D.C., et al., Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med, 2001. 29(7): p. 1303-10.

ORDERING INFORMATION

Please call our Customer Service Department 800-228-6090 for assistance. Additional information can be found online at streck.com.

TECHNICAL SUPPORT

Please call Streck Technical Services at 800-843-0912 for assistance. Additional information can be found online at streck.com.

See the Instructions (IFU) tab under Resources on the product page at streck.com.

See streck.com/patents for patents that may be applicable to this product.

All product names, logos, brands, and marks are property of their respective owners.



350843-1
Date of Issuance: 2025-09